Skip to main content
. Author manuscript; available in PMC: 2012 Mar 24.
Published in final edited form as: N Engl J Med. 2011 Mar 24;364(12):1144–1153. doi: 10.1056/NEJMra1010600

Figure 2. Risk of Hospitalization among Patients Who Underwent VKORC1 and CYP2C9 Genotyping, as Compared with a Historical Control Group, 6 Months after the Initiation of Warfarin Therapy.

Figure 2

Shown are the rates of hospitalization for any cause (Panel A) and for bleeding or thromboembolism (Panel B). There was a significant benefit for patients who had undergone genotyping for the presence of VKORC1 and CYP2C9 variants that have been significantly associated with the risk of over-anticoagulation. Data are from Epstein et al.25